As most, if not all responsible adults in professional positions have potential conflicts of interest, the Journal has decided to instigate the following policy. By conflicts of interest we mean relationships, allegiances or hostilities to particular groups, organisations or interests, which may influence excessively one's judgements or actions. The issue is particularly sensitive when such interests are private and/or may result in personal gain.
Our expectation is that authors will always endeavour to recognise such interests and to act independently when giving their opinions or presenting data. However, it is also now essential that they are seen to acknowledge potential risks, especially where these might be interpreted to their discredit and to the discredit of the Journal of Psychopharmacology.
To this end, we encourage authors to disclose what potential conflicts of interest they have. However, the Journal of Psychopharmacology can accept no responsibility for omissions or lack of clarity -this must rest with the author.
As guidance, the risks that should be addressed lie in particular areas:
1. Where individuals have patents or inventions from which they may derive personal benefit in the area of psychopharmacology.
2. Where there is ownership or part ownership of a company with interests in the area of psychopharmacology. This would include holding the shares of major companies in one's own name, or those of dependent family members.
3. Accepting a personal retainer from any company with an interest in psychopharmacology 4. Acting as a consultant to any company with an interest in psychopharmacology.
5. Acting as an expert witness, either friendly or hostile to any company with an interest in psychopharmacology.
6. Holding a research grant from any company with an interest in psychopharmacology.
7. Membership of the speakers' bureau for any company.
8. The acceptance of paid speaking engagements in industry supported symposia.
9. The acceptance of travel or hospitality not related to a speaking engagement.
Related concerns are appropriate if the relationships implied under any of items 3-9 also exist in respect of a relationship to a voluntary organisation, a charity, a law firm, a department of government, an investment company or any other formally constituted body with interests in the field of psychopharmacology. It is not expected that the details of financial arrangements should be disclosed.
